Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy

NCT03435848 is registered in ClinicalTrials.gov with BioSight Ltd. as lead sponsor.

NCT NCT03435848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03435848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy
Lead sponsor
BioSight Ltd.
Phase
Phase 2
Overall status
Completed
Start date
August 14, 2018
Completion date
March 16, 2023
Enrollment
66 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia